Martin Shkreli Banned From Drug Industry, Must Disgorge $64M For Daraprim Monopoly
NEW YORK — A New York federal judge on Jan. 14 found that former pharmaceutical executive Martin Shkreli engaged in anticompetitive conduct in his marketing of the antiparasitic drug Daraprim, ordered...To view the full article, register now.
Already a subscriber? Click here to view full article